Regulating TGF beta signalling at the transcriptional level and in cancer
To understand, treat, cure and ultimately prevent cancer we must first be able to understand the basic mechanisms that regulate normal cell growth. One of the cellular factors involved both in normal development and in malignant t...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TGFB IN CRC
TGF beta signaling in colorectal cancers
30K€
Cerrado
SelectiveTGFb-inhib
Pro tumorigenic effects of TGFb elucidation of mechanisms...
3M€
Cerrado
BFU2014-53787-P
COMUNICACION CELULAR VIA TGFB-SMADS Y DIFERENCIACION DE CELU...
206K€
Cerrado
ARKADIA AND CANCER
CHARACTERISATION OF ARKADIA FUNCTION IN THE REGULATION OF SN...
172K€
Cerrado
SMAD1/5 AND CANCER
A novel mode of TGF beta signalling through Smad1 Smad5 phos...
172K€
Cerrado
SAF2013-48849-C2-1-R
TRANSICION EPITELIO-MESENQUIMA Y DESARROLLO TUMORAL: ANALISI...
472K€
Cerrado
Información proyecto TGF-BETA AND CANCER
Líder del proyecto
CANCER RESEARCH UK LBG
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
234K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
To understand, treat, cure and ultimately prevent cancer we must first be able to understand the basic mechanisms that regulate normal cell growth. One of the cellular factors involved both in normal development and in malignant transformation is transforming growth factor b TGFb. TGFb is a multifunctional cytokine which, in addition to cancer is also implicated in developmental disorders, fibrosis and autoimmune diseases. TGFb signalling has been implicated in both tumour suppression and progression. Although TGFb inhibits inhibits growth of early carcinomas, later in tumourogenesis, it can induce an epithelial-mesenchymal transition (EMT), promoting an invasive, metastatic tumour phenotype. TGFb signals through the activation of Smad proteins. After activation, Smads accumulate in the nucleus where they regulate transcription, either positively or negatively. Although some recent advances have been made, exactly how Smads regulate transcription and how in turn the Smads are regulated during transcription is still remains unclear. The first aim of this application is to investigate which components of the transcriptional machinery get recruited to the active promoters after TGFb stimulation. In order to achieve this an siRNA library screen targeting histone modifying enzymes and chromatin remodelling proteins will be performed. As mentioned above TGFb has growth inhibitory effects, which are counteracted by Smad7, a negative regulator of the pathway. Although Smad7 has not been identified as an oncogene to date, a genome-wide association screen of tag SNPs performed by our collaborator, has implicated Smad7 as being highly correlated to colorectal cancers. The second aim of this application is to reveal the molecular mechanisms behind this correlation. As colorectal cancers are the second most prevalent malignancy in Europe, understanding how Smad7 affects this process may have wide implications both for the treatment, as well as for the screening of the disease.